@danpharma

Consultant and industry commentary with @Citeline @evaluatepharma, tracking and analysing major biopharma trends. @TimperleyHockey at the weekends.

 Manchester, England
Joined February 2012
  • Tweets799
  • Following273
  • Followers587
16Media
Nordic life science companies have done well in the past decade, @Citeline’s data shows. @SwedenBIO @NLSDays nordiclifescience.org/a-posi…

A positive decade for Nordic life science - NLS

Despite some hiccups along the way caused by global upheavals, the region’s industry continues to trend upwards.

nordiclifescience.org
3
7
362
Daniel Chancellor retweeted
ABPI
@ABPI_UK16 Jan 2023
A powerful message from @Bayer in the @FT today speaking to @hannahkuchler. Europe (including the UK) are becoming 'innovation unfriendly' as governments make it more difficult to generate commercial returns on investments. Read it in full (£) on.ft.com/3CQl6dm
3
7
524
Daniel Chancellor retweeted
Mandy Jackson@ScripMandy12 Jan 2023
I had some great conversations at #JPM23 with companies and investors generally optimistic about the way forward for biopharma in 2023. In case you missed, see our free-to-read coverage of the meeting. (1/3) scrip.pharmaintelligence.inf…
2
1
3
645
Daniel Chancellor retweeted
Ian Haydock@ScripIanHaydock30 Nov 2022
.@ScripMandy parses the full data for #lecanemab in #Alzheimers presented at #CTAD22 including the safety concerns prominent in recent days #pharma Eisai/Biogen’s Lecanemab Effective Across Endpoints, But Will Safety Limit Use? scrip.pharmaintelligence.inf…
3
3
Daniel Chancellor retweeted
EBD Group@EBDgroup8 Nov 2022
In today’s environment, Europe may not match the US in scale, and is challenged by emerging markets, but it still has a central role in partnering and notable strengths, writes @danpharma on the current market situation. Get the white paper here >> spr.ly/6016MQPBk
1
1
Daniel Chancellor retweeted
Bruce Booth
@LifeSciVC7 Nov 2022
Here’s the Atlas Venture 2022 Year In Review. This year, given the 2+ year rollercoaster in the mkts, we start with a deep dive into both the public and private #biotech capital markets, then to the industry overall, closing with an update on ⁦Atlas youtu.be/LONM9ekseJ4

Atlas Venture Year in Review 2022 B. Booth

Atlas Venture partner and LifeSciVC author Bruce Booth shares his Y...

youtube.com
12
49
16
274
This new article analyses the R&D pipelines of the top 20 Chinese pharma companies and the 20 non-Chinese multinational pharma companies to gain a clearer picture of where China's pharmaceutical industry stands globally in terms of innovative R&D go.nature.com/3SB4Thm
1
15
1
51
Biopharma dealmaking in 2021 go.nature.com/3fApgtX Oncology deals continued to be prominent in another strong year for dealmaking - find out more in this new analysis from @amandamicklus and Patricia Giglio
5
9
Daniel Chancellor retweeted
Mandy Jackson@ScripMandy10 Jan 2022
CEO Vas Narasimhan said $NVS plans to go from 73% small molecules, 22% biologics & 5% gene tx, RNA, cell therapy & other modalities to more than half of R&D pipeline in 2030 comprised of biologics & other modalities. And it wants to be partner of choice for gene tx etc. #JPM22
4
1
13
Pharma Outlook 2022: What Next After A Year Of Innovation And Growth? bit.ly/30nEoa0
3
1
Daniel Chancellor retweeted
Eleanor Malone@ScripEleanor21 Sep 2021
Are you an expert in US pharma pricing, reimbursement & markets? Can you write compelling news/analysis for pharma decision makers? We want to recruit a journalist to build a beat around commercial strategy, drug pricing and the payer environment for Scrip lnkd.in/erXaqQnr

LinkedIn

This link will take you to a page that’s not on LinkedIn

lnkd.in
2
2
2
Daniel Chancellor retweeted
Sara Jane Demy@demy_sara10 Jun 2021
Join us June 30 at 11 am ET for this #virtualevent with Ly Nguyen-Jatkoe @Pharma_Intell, Mark Gordon, Friedrich von Bohlen @MolecularHealth, and @danpharma. “Humans vs Machines: The Trial Prediction Challenge Series'' Register here: bit.ly/3zjwqeQ @demycolto
2
1
Daniel Chancellor retweeted
Derrick@dgingery8 Jun 2021
Big thread outlining our Aduhelm package...Story 1, the main bar: Aducanumab Accelerated Approval Reflects US FDA Flexibility But Raises Doubts About Confirmatory Trial pink.pharmaintelligence.info…
1
1
1
Daniel Chancellor retweeted
Mandy Jackson@ScripMandy7 Jun 2021
$BIIB Aducanumab list price is $56,000 per year; $4,312 per infusion. investors.biogen.com/news-re…
2
2
2
Daniel Chancellor retweeted
Alexander Gaffney
@AlecGaffney7 Jun 2021
Aducanumab label is finally online: accessdata.fda.gov/drugsatfd…
6
5
Daniel Chancellor retweeted
Florian Krammer
@florian_krammer13 Apr 2021
If - and there is no solid data on J&J yet - if this is also a rare issue with J&J, then it is likely connected to vector-based vaccines. Would be interesting to see what the data says for Sputnik V and CanSino.
This quoted post is unavailable.
Try viewing anyway · View on X
37
116
15
451
Learn what’s driving #pharma success rates with @InformaPLC @blackstone @Pharma_Intell @danpharma @SagientSara @DavidThomasCFA #BIOCEO21 nuvi.me/952r4w
2
1
Complexity Has Benefits: Data Show Biologics, Targeted Agents Have Better Approval Prospects bit.ly/2NhA3i1 #PharmaScrip
1
1
Daniel Chancellor retweeted
Sarah Karlin-Smith@SarahKarlin9 Feb 2021
FDA advisory panel votes 10-0 that an FDA decision on Keytruda for early stage, high risk triple negative breast cancer should be deferred until there is more data. $MRK
1
7
1
11
Daniel Chancellor retweeted
Eric Topol
@EricTopol23 Nov 2020
The 2 main explanations for the AZ/Oxford vaccine efficacy by dosing differences 1. Low dose: blunts immune response to the adenovirus vector 2. Statistics: the 95% confidence intervals overlap nature.com/articles/d41586-0… @NatureNews @ewencallaway Need more data to determine 1 vs 2
16
87
16
256
Load more